The density of TAMs within the tumor milieu has been positively associated with PD-L1 expression on tumor cells, spotlighting TAMs as potential targets for combination therapies to enhance the responsiveness to immune checkpoint blockade (ICB) therapies, particularly in nasopharyngeal carcinoma (NPC) treatment (Deng et al. 2020). This evidence concerns the gene CD274 and nasopharyngeal carcinoma.